444 results on '"Chambost, H."'
Search Results
2. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
3. Bleeding phenotype according to factor level in 825 children with non-severe hemophilia; data from the PedNet cohort
4. Accompagnement en onco-hématologie pédiatrique : mise en place de plans pharmaceutiques personnalisés pour les enfants traités par anticancéreux oraux
5. PB1249 Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents with Severe Hemophilia A
6. PB0650 Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Pediatric Patients with Hemophilia B: A Review of Results from Phase 3 Trial Studies
7. OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1
8. OC 43.1 A Survey on Clinical Praxis in Initiating Emicizumab Prophylaxis in Previously Untreated Patients in the PedNet Centers
9. PB0638 Final Data from A-MOVE: 12-Month Prospective Multicentre Study to Investigate the Impact of Systematic Joint Examination on Treatment Management Decisions in Patients with Hemophilia A in France
10. Mise au point : diagnostic d’hyperéosinophilie chez l’enfant
11. Dispositif pluridisciplinaire d’accompagnement des enfants et de leur famille depuis l’annonce diagnostique d’une forme sévère d’hémophilie
12. Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis
13. Actualité sur le risque de survenue d’inhibiteur à l’initiation du traitement par concentré de facteur VIII dans l’hémophilie A sévère
14. Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study
15. Transfusion plaquettaire et iso-immunisation anti-Rh1 : intérêt de la séroprévention
16. Hémorragie intracrânienne compliquant un purpura thrombopénique immunologique aigu de l’enfant : une étude rétrospective nationale
17. Le programme L.E.A., suivi prolongé après traitement d’une leucémie aiguë de l’enfance : structuration, résultats et perspectives
18. Full but impaired activation of innate immunity effectors and virus-specific T cells during CMV and EBV disease following cord blood transplantation
19. Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study
20. Efficacy, pharmacokinetics (PK) and safety results of a phase 3 clinical study of recombinant fusion protein linking coagulation factor IX with albumin (RIX-FP) in previously treated children with hemophilia B: OR346
21. Plasma-derived factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A: report of the FranceCoag Network: OR143
22. In haemophilic patients tfpi levels influence thrombin generation profile and TFPI neutralization normalizes thrombin generation potential: OR012
23. Interim results from the prospective observational study on Novoseven® room temperature stable (VII25) in patients with hemophilia A or B: PCI09
24. Cancer detection and management in patients with haemophilia: a retrospective European multicentre study
25. Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI
26. Clinical evidence implicating gamma-delta T cells in EBV control following cord blood transplantation
27. Health status and quality of life in long-term survivors of childhood leukaemia: the impact of haematopoietic stem cell transplantation
28. CD34+ progenitors are reproducibly recovered in thawed umbilical grafts, and positively influence haematopoietic reconstitution after transplantation
29. Long-term follow-up of neonatal intracranial haemorrhage in children with severe haemophilia
30. Treatment of girls and women with haemophilia A and haemophilia B: a retrospective study in the francecoag cohort
31. Time to negative inhibitor titre in severe haemophilia a patients with low titre inhibitors is similar regardless of iti treatment data from pednet cohort
32. Impact of haemophilia on cancer detection and management: a retrospective study: PB 4.60–6
33. ORTHem 15–25: French retrospective national survey of different treatment regimens in patients with severe (factor VIII or IX = 2%) haemophilia A and B between 15 and 25 years old: PB 4.36–5
34. Alloimmune thrombocytopenia masking a bernard soulier syndrome in a congenital nephrotic syndrome of the Finnish type (nphs1): PB 4.29–3
35. Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study: PA 2.07–4
36. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry
37. A prospective study of Epstein–Barr virus load in 85 hematopoietic stem cell transplants
38. Enjeux d'une prise en charge pédiatrique précoce de l'hémophilie sévère
39. Fine characterization of childhood and adult acute lymphoblastic leukemia (ALL) by a proB and preB surrogate light chain-specific mAb and a proposal for a new B cell ALL classification
40. Acute myeloid leukaemia triggering via CD40 induces leukocyte chemoattraction and cytotoxicity against allogenic or autologous leukemic targets
41. Immune reconstitution and outcome after unrelated cord blood transplantation: a single paediatric institution experience
42. Perinatal practices in the context of hemophilia carrier: Expert opinion from an international pediatric panel: PO-TU-166
43. Implementation of national recommendations of early prophylaxis in boys with severe hemophilia: Results from the Pups cohort of “FranceCoag network”: PO-TU-156
44. Update data of the FranceCoag Network, the French National Registry for Congenital Bleeding Disorders: PO-MO-024
45. Age at the first bleeding could be a predictor of hemorrhagic phenotype in patients with severe hemophilia: FP-MO-04.4-2
46. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38− leukemic progenitors
47. A new mutation in the FERMT3 gene causes the absence of kindlin-3 in platelets and leukocytes: consequences on integrin dependent and independent adhesion: O-TH-004
48. Health related quality of life in French haemophilia population: a comparative analysis with French general population: 31P12
49. Hemophilia A genotyping using DHPLC: experience concerning 486 patients: 21P24
50. New data from the ONE Registry: 10P09
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.